American songwriters and performers achieved a rare feat in a highly polarized and partisan political environment: unite policymakers from all sides of the House of Representatives, and even get on board tech companies and broadcasters to support the m…Continue Reading ...
A new affordable combination treatment for hepatitis C patients with a 97 percent cure rate was announced today.Continue Reading ...
In the face of the growing threat of antimicrobial resistance, a recent study of the Proceedings of the National Academy of Sciences of the United States of America (PNSA) found that the antibiotic consumption rate in low and middle-income countries ha…Continue Reading ...
President Trump’s recently halting Broadcom from a hostile takeover of Qualcomm is good news for American national security. Some have cast the administration’s intervention as “protectionism.” Those people are ignoring the main point. The president’s order preserving the U.S. firm’s independence acted, as the Wall Street Journal said, on “national-security concerns in this case [that] are legitimate.” … Had Mr. Trump not stopped Broadcom, U.S.-based technology may not set the standards —…
Continue Reading ...
a bipartisan group of Representatives serving on the House Judiciary Committee introduced the Music Modernization Act (H.R. 5447) into the U.S. House of Representatives. Along with broad political support, the Music Modernization Act reportedly has wid…Continue Reading ...
On Tuesday, April 10, 2018, a federal jury in Eastern District of Texas awarded VirnetX Holding Corp. (VHC) with a $502.6 million verdict against Apple Inc. finding that Apple was infringing 4 secure communications patents – providing a new chapter to the now eight-year old battle between Zephyr Cove, Nevada based VirnetX and Cupertino-based Apple, Inc.
The post VirnetX Awarded $502.6 Million in Fourth Jury Trial against Apple appeared first on IPWatchdog.com | Patents & Patent Law.
Continue Reading ...
By Aaron Gin — “The first and only autonomous AI system authorized by the FDA” On April 11, 2018, the U.S. Food and Drug Administration (FDA) permitted marketing of a medical device that utilizes artificial intelligence to diagnose eye disease in diab…Continue Reading ...
(CIRCUMSTANCES)Continue Reading ...
$$ A particular advantage of the present invention is that it allows the use of a fibrin sealant in circumstances where the patien…
Bloomberg reported:VirnetX Holding Corp. won $502.6 million against Apple Inc. after a federal jury in Texas said the maker of iPhones was infringing patents for secure communications, the latest twist in a dispute now in its eighth year.Continue Reading ...
The basis for the challenge:
Merck’s challenge ultimately rests on its contention
that the Board’s reading of van Etten, on which the
Board’s findings of fact rest, is simply unreasonable and
therefore unsupported by substantial evidence. See
TriVascular, Inc. v. Samuels, 812 F.3d 1056, 1061 (Fed.
Cir. 2016) (“Substantial evidence ‘means such relevant
evidence as a reasonable mind might accept as adequate
to support a conclusion.’”) (quoting Consol. Edison Co. v.
NLRB, 305 U.S. 197, 229 (1938)). This standard does not
require the Board’s reading of van Etten to be the only
reasonable one for us to uphold it. “[T]he possibility of
drawing two inconsistent conclusions from the evidence
does not prevent an administrative agency’s finding from
being supported by substantial evidence.” Consolo v. Fed.
Maritime Comm’n, 383 U.S. 607, 620 (1966); see In re
Jolley, 308 F.3d 1317, 1320 (Fed. Cir. 2002) (“If the evidence
in record will support several reasonable but contradictory
conclusions, we will not find the Board’s
decision unsupported by substantial evidence simply
because the Board chose one conclusion over another
plausible alternative.”); AK Steel Corp. v. United States,
192 F.3d 1367, 1371 (Fed. Cir. 1999).
The CAFC did not adopt Merck’s view:
Continue Reading ...
We need not and do not decide whether Merck’s view
of what van Etten teaches is the better view. We conclude
only that Merck’s view is not the only reasonable view.
Above we italicized excerpts from van Etten that support
the key findings of the Board. Those excerpts are reasonably
capable of being read as conveying sufficiently positive
implications about the use of folate alone—without
also administering other substances, like serotonin,
related to NO-mediated endothelial-dependent vasomotor
responses—that they would provide a relevant skilled
artisan a motivation to do what claim 35 requires with a
reasonable expectation of success and not leave the artisan
discouraged from doing so by the article as a whole
within the meaning of the “teaching away” principle. See,
e.g., DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.,
567 F.3d 1314, 1327 (Fed. Cir. 2009).
USPTO Director Andrei Iancu gave the keynote address at the April 11, 2018 Patent Policy Conference hosted by the U.S. Chamber of Commerce. The following is an excerpt: … Dr. Eli Harari … risked everything: his career, his finances, and his family. That first company actually did not work out well, but a few years […]Continue Reading ...
- Actual Use vs Inherent Disclosure: Endo v. Custopharm
- Pro se Appellant Burnett loses in a 12(b)(6)/101 case
- Global Innovation Divide: Can Investment In Innovation Bridge The Gap?
- CAFC finds D. Del. erred in claim construction in Blackbird v. ELB; Judge Reyna dissents
- Legislation Introduced in House to Repeal the PTAB and the AIA